Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine

被引:47
作者
Chan Kwong, Anna H. -X. P. [1 ,2 ,3 ,4 ]
Calvier, Elisa A. M. [4 ]
Fabre, David [4 ]
Gattacceca, Florence [3 ]
Khier, Sonia [1 ,2 ]
机构
[1] Montpellier Univ, Sch Pharm, Pharmacokinet & Modeling Dept, Montpellier, France
[2] Montpellier Univ, CNRS, Inst Montpellierain Alexander Grothendiec IMAG, Probabil & Stat Dept,UMR 5149, Montpellier, France
[3] Aix Marseille Univ, CRCM, Inst Paoli Calmettes, SMARTc Grp,Inserm,CNRS, Marseille, France
[4] Sanofi R&D, Translat Med & Early Dev, Pharmacokinet Dynam & Metab PKDM, Montpellier, France
关键词
Population pharmacokinetics; Pharmacokinetic-pharmacodynamic; PRIOR; NONMEM; Guidance; Model; PRIOR DISTRIBUTIONS; MODEL; METABOLITES;
D O I
10.1007/s10928-020-09695-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Population pharmacokinetic analysis is used to estimate pharmacokinetic parameters and their variability from concentration data. Due to data sparseness issues, available datasets often do not allow the estimation of all parameters of the suitable model. The PRIOR subroutine in NONMEM supports the estimation of some or all parameters with values from previous models, as an alternative to fixing them or adding data to the dataset. From a literature review, the best practices were compiled to provide a practical guidance for the use of the PRIOR subroutine in NONMEM. Thirty-three articles reported the use of the PRIOR subroutine in NONMEM, mostly in special populations. This approach allowed fast, stable and satisfying modelling. The guidance provides general advice on how to select the most appropriate reference model when there are several previous models available, and to implement and weight the selected parameter values in the PRIOR function. On the model built with PRIOR, the similarity of estimates with the ones of the reference model and the sensitivity of the model to the PRIOR values should be checked. Covariates could be implemented a priori (from the reference model) or a posteriori, only on parameters estimated without prior (search for new covariates). [GRAPHICS] .
引用
收藏
页码:431 / 446
页数:16
相关论文
共 42 条
[31]   Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters [J].
Milosheska, Daniela ;
Lorber, Bogdan ;
Vovk, Tomaz ;
Kastelic, Matej ;
Dolzan, Vita ;
Grabnar, Iztok .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (02) :399-411
[32]   Population Pharmacokinetic Analysis of Voriconazole from a Pharmacokinetic Study with Immunocompromised Japanese Pediatric Subjects [J].
Muto, Chieko ;
Shoji, Satoshi ;
Tomono, Yoshiro ;
Liu, Ping .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) :3216-3223
[33]   Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis [J].
Naidoo, Anushka ;
Chirehwa, Maxwell ;
Ramsuran, Veron ;
McIlleron, Helen ;
Naidoo, Kogieleum ;
Yende-Zuma, Nonhlanhla ;
Singh, Ravesh ;
Ncgapu, Sinaye ;
Adamson, John ;
Govender, Katya ;
Denti, Paolo ;
Padayatchi, Nesri .
PHARMACOGENOMICS, 2019, 20 (04) :225-240
[34]  
Nemoto A, 2017, CURR THER RES CLIN E, V84, P42, DOI 10.1016/j.curtheres.2017.04.001
[35]  
Pérez-Ruixo JJ, 2011, AAPS ADV PHARM SCI, V1, P311, DOI 10.1007/978-1-4419-7415-0_14
[36]   Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling [J].
Quartino, Angelica L. ;
Karlsson, Mats O. ;
Lindman, Henrik ;
Friberg, Lena E. .
PHARMACEUTICAL RESEARCH, 2014, 31 (12) :3390-3403
[37]   Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children [J].
Robbie, Gabriel J. ;
Zhao, Liang ;
Mondick, John ;
Losonsky, Genevieve ;
Roskos, Lorin K. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (09) :4927-4936
[38]   A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection [J].
Sadiq, Muhammad W. ;
Nielsen, Elisabet I. ;
Khachman, Dalia ;
Conil, Jean-Marie ;
Georges, Bernard ;
Houin, Georges ;
Laffont, Celine M. ;
Karlsson, Mats O. ;
Friberg, Lena E. .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 (02) :69-79
[39]   Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus [J].
Saito, Masako ;
Kaibara, Atsunori ;
Kadokura, Takeshi ;
Toyoshima, Junko ;
Yoshida, Satoshi ;
Kazuta, Kenichi ;
Ueyama, Eiji .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (08) :1808-1819
[40]   Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma [J].
Samuel Perez-Blanco, Jonas ;
Santos-Buelga, Dolores ;
del Mar Fernandez de Gatta, Maria ;
Maria Hernandez-Rivas, Jesus ;
Martin, Alejandro ;
Jose Garcia, Maria .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (06) :1517-1527